Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa

A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.

[1]  L. Leibovici,et al.  The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  R. Bonomo,et al.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  B. Kreiswirth,et al.  Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates , 2016, Antimicrobial Agents and Chemotherapy.

[4]  S. Bauer,et al.  Influence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative Bacilli , 2015, Antimicrobial Agents and Chemotherapy.

[5]  M. Gelfand,et al.  Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Christina A. Sutherland,et al.  Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals. , 2015, Clinical therapeutics.

[7]  Ronald N. Jones,et al.  Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012) , 2013, Antimicrobial Agents and Chemotherapy.

[8]  J. Karlowsky,et al.  In Vitro Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals in the CANWARD Study, 2007 to 2012 , 2013, Antimicrobial Agents and Chemotherapy.

[9]  S. Bauer,et al.  Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  G. Bodey,et al.  Colistin Is Effective in Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa in Cancer Patients , 2007, Antimicrobial Agents and Chemotherapy.

[11]  R. Bonomo,et al.  Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  D. Paterson,et al.  Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  A. Levin,et al.  Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.